Make space on your watchlist: These Strong Buy upgrades are coming in hot:
-
Newmont Corp (NEM) — Gold giant eyes 61% upside on record earnings.
-
LivaNova PLC (LIVN) — FDA approval fuels MedTech momentum and analyst confidence.
-
Atlassian Corp (TEAM) — Stock soars 28% on AI-driven cloud growth surge.
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
"This stock has a 93% history of soaring, every spring"
One of the most popular stocks in America has a 100% history of rising on one particular date - every single spring.
In fact, it's gone up beginning this ONE specific day - year after year - at a rate fast enough to double your money in 12 months.
Click here to see the name of the stock, free of charge.
As the world's leading gold mining company with operations across four continents, Newmont is striking gold — literally. With gold prices stabilizing and record-breaking quarterly results in the books, NEM is perfectly positioned to capitalize on strong market fundamentals and ramped-up operational efficiency.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $115.26 — get current quote
Max 1-year forecast: $176.00
Here are 3 BIG reasons why we’re watching:
- Strong analyst support: NEM attracts coverage from 6 top-rated analysts, and every last one of them is bullish. It currently has 2 Strong Buy and 4 Buy ratings — no Hold, Sell, or Strong sells. For example, CiBC researcher Anita Soni (a top 4% rated analyst) recently maintained her Buy rating with a $176 price target (+61.45% upside), believing that NEM is undervalued based on current metrics following strong earnings results that beat estimates by 5.88%. See the ratings
- Strong stock in a strong industry: NEM is currently the 7th highest-rated stock in the Gold industry, which has an Industry Rating of B. It was also featured in our video about high-potential mining stocks.
- Excellent Zen Rating: NEM earns an overall A or Strong Buy rating, putting NEM in a class of stocks that have historically delivered market-beating returns annually. Looking at the Component Grades, NEM shines with an A grade in Financials, B grades in Value, Momentum, and our proprietary AI factor. (See all 7 Zen Component Grades here)
This global medical technology powerhouse just delivered a one-two punch: Q1 2026 earnings that crushed estimates and raised full-year guidance, plus a fresh FDA approval for its aura6000 System targeting obstructive sleep apnea. No wonder LIVN is suddenly the medical device sector's hottest name.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $57.59 — get current quote
Max 1-year forecast: $81.00
Here are 3 BIG reasons why we’re watching:
- Top-rated analysts like it: LIVN draws coverage from 6 analysts with a consensus of Buy, featuring 2 Strong Buy ratings, 3 Buy ratings, and 1 Hold rating. For example, Stifel Nicolaus' Rick Wise (a top 15% rated analyst) recently maintained his Strong Buy rating with a $70 price target (+21.55% upside), noting in a 2026 preview that the setup for Large-cap MedTech is constructive after 2025 pressures, with LIVN positioned to benefit from sector tailwinds. Additionally, a Needham analyst recently maintained a Buy rating with an $81 price target (+40.65% upside). See the ratings
- Good juju: LIVN is worth watching after it posted a strong Q1 earnings beat, raised full-year 2026 guidance, and gained momentum from new FDA approvals plus improving reimbursement trends in its epilepsy and sleep apnea businesses.
- Awesome Zen Rating: LIVN earns an overall A or Strong Buy from our Zen Ratings — the highest grade possible, and a sign of higher-than-normal probability of outperformance. Looking at the Component Grades, LIVN shows balanced strength with B grades in Growth, Safety, Financials, and from our proprietary AI factor. (See all 7 Zen Component Grades here)
The enterprise software giant behind Jira, Confluence, and Trello just sent shockwaves through Wall Street — TEAM's stock soared 28% after a double earnings and revenue beat fueled by explosive cloud and data center growth. Now, with agentic AI initiatives in the spotlight, analysts can't stop watching.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $88.87 — get current quote
Max 1-year forecast: $304.00
Here are 3 BIG reasons why we’re watching:
- Extremely bullish analyst sentiment: Among the 18 analysts we track issuing ratings, TEAM enjoys 11 Strong Buy ratings, 5 Buy ratings, and 2 Hold ratings, reflecting strong conviction in the company's growth trajectory. See the ratings
- Jaw-dropping upside potential: Piper Sandler's Rob Owens (a top 4% rated analyst) maintains a Strong Buy rating with a $175 price target (+89.50% upside), highlighting TEAM's successful execution on cloud migration and the potential for agentic AI features to drive substantial revenue expansion.
- Impressive Zen Ratings: TEAM was recently upgraded to an A (Strong Buy) in our system, a class of stocks that has historically delivered 32.52% annual returns. Looking at the Component Grades that shape the overall rating, TEAM excels with A grades in Growth, Sentiment, and Financials, plus a B grade from our AI factor. On top of that, TEAM is currently the 7th highest-rated stock in the App industry, which has an Industry Rating of B. (See all 7 Zen Component Grades here)
What to Do Next?